Sucampo to Release Third Quarter 2009 Financial Results and Conduct a Conference Call on November 5, 2009
More News related to SCMP
- Sucampo Pharma (SCMP) Presents Additional Clinical Data for Lubiprostone
- Sucampo Announces Lubiprostone Data Presented at GASTRO 2009 UEGF/WCOG
- Sucampo Pharma (SCMP) Subsidiary Granted Marketing Authorization for Amitiza in Switzerland
- Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation
- Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference
More News related to Press Releases
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
BETHESDA, Md.--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2009. These results are expected to be released on Thursday, November 5, 2009, after the capital markets close.
The conference call will be hosted by senior management and will be held at 4:30 p.m. Eastern on Thursday, November 5, 2009.
Investors may listen to the live call by dialing 866-783-2138 (domestic) or 1-857-350-1597 (international), passcode 31403000 five to ten minutes ahead of the start of the call. A replay of the call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-286-8010 (domestic) or 1-617-801-6888 (international), passcode 52346247.
The conference call will be webcast and may be accessed at the "For Investors" section of the company's website, www.sucampo.com. Investors interested in listening to the live audio webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors.
Sucampo Pharma America, Inc., markets AMITIZA(R) (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and AMITIZA 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals, Inc. has three wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., located in the UK; Sucampo Pharma, Ltd., located in Japan; and, Sucampo Pharma Americas, Inc., located in Maryland. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.
Source: Sucampo Pharmaceuticals, Inc.
Related Categories
Press ReleasesStocks Mentioned
-0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
